Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cell
Turkish Journal of Biology · 20.12.2024 · 48 (6) · 401-413
DOI: 10.55730/1300-0152.2715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Biology, online erschienen am 20.12.2024. Verfasst von Zeynep Işlek Köklü und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Melanoma arises from the uncontrolled multiplication of melanocytes, posing an escalating global health concern. Despite early detection and surgical removal being crucial, metastatic melanoma poses treatment challenges, with limited options like chemotherapy and immunotherapy. All-trans retinoic acid (ATRA), a natural metabolite of vitamin A, has shown promise in melanoma treatment by inducing differentiation, apoptosis, growth arrest, and immune modulation. However, ATRA treatment alone can lead to resistance and relapse. Sphingomyelin (SM) also plays a role in inhibiting melanoma progression by apoptotic cell death.
Objective
This study investigated combinational anticancer effects of ATRA and SM on in vitro B16F10 melanoma cells.
Method
The combinational anticancer effects were evaluated based on viability, apoptotic death, cell cycle progression, and caspase, Bax, Anti-Programmed Cell Death Ligand 1 (Anti-PD-L1), and Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) gene expressions; whereas the safety properties were tested on RAW264.7 macrophages. The datasets underwent initial ordinary one-way analysis of variance (ANOVA), followed by two-way ANOVA, and were subsequently scrutinized by Tukey's multiple comparison test.
Results
The combination of 123 µM ATRA and 136 µM SM significantly reduced B16F10 proliferation by 50%, induced 53.91% apoptosis within 48 hours, and caused G2/M phase-cell cycle arrest. Combinational therapy increased Cas 3 and Bax gene expressions by 2-fold and 5-fold, respectively, while enhancing CDKN2A expression by 13-fold and suppressing Programmed Death Ligand 1 expression by 0.5-fold.
Conclusion
The ATRA and SM combination could be a promising therapeutic approach for melanoma, potentially improving efficacy while relatively reducing toxicity to healthy cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.
ORCID-Profile: Zeynep Işlek Köklü, Elif Lidya Şanverdi, Başak Karadağ, Mehmet Hikmet Üçişik, Ezgi Taşkan, Fikrettin Şahin
Zitieren
APA
Işlek Köklü, Z., Şanverdi, E. L., Karadağ, B., Üçişik, M. H., Taşkan, E., & Şahin, F. (2024). Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cell. Turkish Journal of Biology, 48(6), 401-413. https://doi.org/10.55730/1300-0152.2715
Vancouver
Işlek Köklü Z, Şanverdi EL, Karadağ B, Üçişik MH, Taşkan E, Şahin F. Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cell. Turkish Journal of Biology. 2024;48(6):401-413. doi:10.55730/1300-0152.2715
BibTeX
@article{IlekKkl2024,
author = {Işlek Köklü, Zeynep and Şanverdi, Elif Lidya and Karadağ, Başak and Üçişik, Mehmet Hikmet and Taşkan, Ezgi and Şahin, Fikrettin},
title = {Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cell},
journal = {Turkish Journal of Biology},
year = {2024},
volume = {48},
number = {6},
pages = {401--413},
doi = {10.55730/1300-0152.2715}
}
EUVIMED